跳至主要内容
临床试验/NCT06537947
NCT06537947已完成不适用

A Single Center, First in Human Study to Evaluate the Feasibility of the SENTANTE Robotic System Application in Peripheral Endovascular Interventions

Inovatyvi Medicina UAB2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2024年7月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
2
主要终点
Safety endpoint: Number of procedures without adverse device effects (ADEs)

研究概览

简要总结

The objective of the study is to evaluate the feasibility, safety and initial efficacy of the clinical and technical performance of the SENTANTE robotic system in the remote delivery and manipulation of commonly used and compatible guidewires and catheter-based devices for use in peripheral endovascular procedures.

The study will be a single-center, prospective investigation, designed to evaluate the safety, feasibility, and initial efficacy of robotic system for remote endovascular interventions in adults with disease which requires peripheral endovascular treatment with compatible devices. Participants meeting the inclusion criteria will undergo endovascular interventions using SENTANTE robotic system. Data will be collected through clinical assessments, imaging and other studies, laboratory tests, and feedback from medical personnel and patients.

The study will adhere to ethical guidelines, obtain informed consent from all participants, and be conducted under the oversight of the Clinical Events Committee.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
19 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is ≥ 19 years and ≤ 90 years of age.
  • Subject is willing and able to provide appropriate study-specific informed consent and follow Clinical Investigation Plan (CIP) procedures.
  • Life expectancy ≥ 12 months from the date of the index procedure.
  • Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study.
  • Subject is diagnosed with a disease which requires peripheral endovascular intervention using compatible with SENTANTE guidewires and catheter-based devices.

排除标准

  • Planned interventional procedure or surgery of the carotid, coronary or peripheral arteries within 30 days before or after the index procedure.
  • Subjects with myocardial infarct or cerebrovascular event within 3 months prior to index procedure.
  • Severe vascular anatomy that would preclude safe sheath insertion, or deliverability of stent.
  • History of bleeding diathesis or coagulopathy.
  • History of thrombophilia.
  • Sensitivity to contrast media that cannot be adequately pre-treated.
  • Sensitivity to both forms of CIP-acceptable anticoagulation strategies (i.e., both heparin AND Bivalirudin).
  • Sensitivity to an antiplatelet agent AND all CIP acceptable alternative antiplatelet options.
  • Major neurologic deficit with NIHSS of ≥
  • Clinical condition that, in the opinion of the investigator, makes endovascular therapy impossible or hazardous.
  • Subject previously enrolled in this clinical trial.
  • Possible / probable non-compliance of subject with CIP required follow up or medication.
  • Subject is currently participating in another clinical trial that has not completed its primary endpoint assessment or would confound this Clinical Study.
  • Signs of SARS-CoV2 (COVID-19) active infection.
  • Patients with intervention-related anxiety, separation anxiety, autophobia and individuals that cannot be left alone without additional sedation or close supervision.

结局指标

主要结局

Safety endpoint: Number of procedures without adverse device effects (ADEs)

时间窗: Immediately after intervention and after 96 hours post procedure or hospital discharge if comes first

Safety level counted per procedure basis, defined as absence of evidence of device related clinically significant vessel injury, with particular emphasis on events such as: i. Perforation, ii. Thrombosis, iii. Flow limiting residual dissection, iv. Distal embolization (excluding embolization procedure). The assessment of the impact of observed ADEs on the safety profile of the robotic system will be based on the Clinical event committee (CEC) adjudication.

Efficacy endpoint: Number of procedures with technical success

时间窗: Immediately after intervention

Technical success rate counted per procedure basis, defined as: i. Diagnostic procedure - placement of diagnostic catheter to intended vessel and performing angiography. ii. PTA/stenting procedure - placement of balloon catheter or balloon expandable stent to intended vessel and effectively expanding it up to nominal pressure. iii. Coiling procedure - implantation of pushable coils or liquid embolization materials (such as microspheres) to an intended vessel.

次要结局

  • Rate of conversion to manual procedure(During the intervention)
  • Nurse feedback on dedicated form(Within 96 hours post procedure)
  • Successful advancement/retrieval of the device without manual assistance(During the intervention)
  • Rate of manual assistance(During the intervention)
  • Clinical success(Immediately after intervention and after 96 hours post procedure or hospital discharge if comes first)
  • Radiation exposure in a typical operator workplace(Immediately after intervention)
  • Procedural satisfaction reported by patients on dedicated form(Within 96 hours post procedure or before hospital discharge if it comes first)
  • Procedural success: Number of procedures with achieved success(Immediately after intervention and after 96 hours post procedure or hospital discharge if it comes first)
  • Safety level at access site(After 96 hours post procedure or before hospital discharge if it comes first)
  • Operator feedback on dedicated form(Within 96 hours post procedure)
  • Clinical events (adverse event (AE)/serious adverse event (SAE)/adverse device effect (ADE)) during the index procedure and till the discharge(Immediately after intervention and within 96 hours post procedure or before hospital discharge if it comes first)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

SENTANTE: Fully Robotic Peripheral Endovascular... | 临床试验